Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MNCs for Radiation-induced Lung Injury
NCT07177456Phase 1Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord blood mononuclear cells in radiation-induced lung injury (RILI), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Chest Enhanced CT Scan report at 12 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on NCT07177456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177456.